Physician profile
Sam Kpahn
NPI 1669019378
$331.66
in general payments reported to CMS, 2019-2025
11 companies · $57.81 in 2025
The $57.81 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.14 · 2022: $59.67 · 2024: $189 · 2025: $57.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $75.75 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.95 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $35.62 | 2024 | Cobenfy |
| Lundbeck LLC | $35.39 | 2024-2025 | Rexulti |
| Alkermes, INC. | $32.81 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $29.30 | 2024 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $28.09 | 2021-2022 | |
| Corium, LLC | $15.48 | 2022 | |
| Almatica Pharma LLC | $13.76 | 2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $13.01 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Kpahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.